TABLE 2.
Most frequently encountered autoantibodies.
| Auto-antibodies | Overall N = 75 |
Amyopathic at diagnosis N = 29 |
Presence of myopathy at diagnosis N = 46 |
| ANA | 30 (40.0%) | 11 (37.9%) | 19 (41.3%) |
| Anti-Jo-1 | 20 (26.7%) | 8 (27.6%) | 12 (26.1%) |
| Anti-Ro-52 | 18 (24.0%) | 7 (24.1%) | 11 (23.9%) |
| Anti-MDA5 | 14 (18.7%) | 8 (27.6%) | 6 (13.0%) |
| Anti-PL-7 | 11 (14.7%) | 6 (20.7%) | 5 (10.9%) |
| Anti-PL-12 | 11 (14.7%) | 3 (10.3%) | 8 (17.4%) |
| Anti-OJ | 9 (12.0%) | 4 (13.8%) | 5 (10.9%) |
| Anti-Ku | 6 (8.0%) | 0 (0.0%) | 6 (13.0%) |
| Anti-Mi-2a | 4 (5.3%) | 3 (10.3%) | 1 (2.2%) |
| Anti-Mi-2b | 4 (5.3%) | 3 (10.3%) | 1 (2.2%) |
| Anti-NXP2 | 3 (4.0%) | 2 (6.9%) | 1 (2.2%) |
ANA, antinuclear antibody; Jo-1, Histidyl-tRNA synthetase; MDA5, melanoma differentiation-associated gene 5; Mi-2a, helicase protein-2a; Mi-2b, helicase protein-2b; NXP2, nuclear matrix protein; OJ, Isoleucyl-tRNA synthetase; PL-7, Threonyl-tRNA synthetase antibodies; PL-12, Alanyl-tRNA synthetase.